ISSN:
1573-0646
Schlagwort(e):
mitogauzone
;
cisplatin
;
vinblastine
Quelle:
Springer Online Journal Archives 1860-2000
Thema:
Chemie und Pharmazie
,
Medizin
Notizen:
Conclusions This trial employing MGBG, vinblastine, and cisplatin in patients with advanced NSCLC produced a 10% response rate with no durable responses. This is disappointing compared to previously cited studies, although the median overall survival of 7.0 months is comparable. The relatively mild toxicity noted in this trial suggests that more aggressive use of the same combination may be feasible.
Materialart:
Digitale Medien
URL:
http://dx.doi.org/10.1007/BF00873920
Permalink